Literature DB >> 27054086

Endobronchial aspergilloma: A case report.

Aysel Sunnetcioglu1, Selami Ekin1, Remzi Erten2, Mehmet Parlak3, Ramazan Esen4.   

Abstract

A 28-year-old male with B-cell acute lymphoblastic leukemia presented to our pulmonary clinic with progressive dyspnea, cough, hemoptysis, and fever. Diagnostic bronchoscopy revealed white masses at the entrance of the right middle lobe bronchus and distal to the right main bronchus. Histopathological examination of the biopsy specimen showed those masses to be hyphae of Aspergillus.

Entities:  

Keywords:  Aspergilloma; Endobronchial; Immunocompetent

Year:  2016        PMID: 27054086      PMCID: PMC4802675          DOI: 10.1016/j.rmcr.2016.03.001

Source DB:  PubMed          Journal:  Respir Med Case Rep        ISSN: 2213-0071


Introduction

Aspergillus spp. can cause a variety of pulmonary diseases, depending on the immune status of the individual and the presence of underlying lung disease. Pulmonary aspergilloma, allergic bronchopulmonary aspergillosis, chronic necrotizing pulmonary aspergillosis, and invasive aspergillosis are the most common clinical presentations of pulmonary infections due to Aspergillus species [1], [2], [3], [4]. Endobronchial aspergilloma is an unusual presentation of pulmonary aspergillosis [5] and is characterized by the growth of Aspergillus species into the bronchial lumen. Endobronchial aspergilloma can mimic endobronchial tumors in terms of the clinical and radiographic presentation. Here, the study describes a case of endobronchial aspergilloma in a patient with B-cell acute lymphoblastic leukemia.

Case report

A 28-year-old male previously diagnosed with relapsed B-cell acute lymphoblastic leukemia presented to our pulmonary clinic with progressive dyspnea, cough, hemoptysis and fever. Auscultation revealed bilateral rhonchi. On admission, the complete blood count results were normal: white blood cells, 5,000/mm3 (41.7% neutrophils, 49.0% lymphocytes, and 0.1% eosinophils); hemoglobin, 8.5 g/dL; and platelets, 18,000/mm3 after chemotherapy. The C-reactive protein level was 57 mg/IU. Bilateral multiple opacities were detected on the chest X-ray (Fig. 1). Computed tomography revealed multiple areas of consolidation distributed randomly throughout the lung (Fig. 2). Bronchoscopy was performed for evaluate the cause of hemoptysis and to diagnose lung parenchymal lesions. Diagnostic flexible bronchoscopy revealed that, distal to the right main bronchus, the right lung middle lobe bronchial entrances were narrowed by a white mass (Fig. 3). A biopsy was obtained from the white mass at the entrance of the middle lobe bronchus. Microscopy of the biopsy samples showed fungal hyphae that stained with Peryodik Asit Shift(PAS) (Fig. 4), and Aspergillus fumigatus was grown in culture. The patient was diagnosed as aspergillosis and voriconazole was started.
Fig. 1

Chest radiogram demonstrating multiple opacities.

Fig. 2

Thorax computed tomogram showing consolidated areas in the lung distributed randomly.

Fig. 3

The bronchoscopy shows a whitish mass lesion causing partially obstruction of distal the right main bronchus (A), and complete obstruction of entrance the middle lobe bronchus (B).

Fig. 4

The histologic examination shows numerous hyphae with background necrotic debris hematoxylin and eosin. ×400(A), Peryodik Asit Shift(PAS) (B).

Discussion

Endobronchial aspergilloma is a rare presentation of pulmonary aspergillosis. It can present as a noninvasive form of aspergillosis characterized by growth of Aspergillus spp. within the bronchi, with or without parenchymal lesions or cavities. Aspergillus airway infection can complicate the course of various malignant diseases, the risk being highest in severely immunocompromised patients with hematological malignancies. The clinical presentation of aspergillosis is quite diverse. Many patients are asymptomatic, although some present with symptoms such as cough, dyspnea, hypoxia, hemoptysis and weight loss. The potential for endobronchial aspergillosis to progress rapidly to respiratory failure has previously been reported [6], [7]. In addition, the need for mechanical ventilation drastically affects mortality rates, which have been reported to be 94% for endobronchial aspergillosis patients on mechanical ventilation, compared with 25% for those not requiring mechanical ventilation [8]. In many cases, endobronchial aspergilloma is incidentally detected in patients who have undergone bronchoscopy to evaluate the cause of hemoptysis and to diagnose parenchymal lung lesions [5]. Bronchoscopic findings vary from yellowish-white necrotic plaques to whitish nodules. Since the most reliable criterion of fungal airway disease is demonstration of tissue invasion and damage caused by hyphae [9], [10], [11], bronchoscopy with biopsy, microscopy, and culture is the only way to confirm invasive Aspergillus tracheobronchial infection in the clinical setting [12]. The optimal treatment or duration of therapy for endobronchial aspergilloma has yet to be established since this unique pre-sentation of Aspergillus seen in immunocompetent indivi-duals are usually diagnosed incidentally. Treatment options include amphotericin B, voriconazole, itraconazole, and caspofungin. Finally, although endobronchial aspergilloma is extremely rare, it should be considered in the differential diagnosis of endobronchial masses in immunocompromised patients.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.
  12 in total

Review 1.  The clinical spectrum of pulmonary aspergillosis.

Authors:  Ayman O Soubani; Pranatharthi H Chandrasekar
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

2.  Pseudomembranous and obstructive Aspergillus tracheobronchitis - optimal diagnostic strategy and outcome.

Authors:  Selçuk Tasci; Axel Glasmacher; Silvia Lentini; Klaus Tschubel; Santiago Ewig; Ernst Molitor; Tilman Sauerbruch; Berndt Lüderitz; Christian Rabe
Journal:  Mycoses       Date:  2006-01       Impact factor: 4.377

Review 3.  Invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

Review 4.  Commentary: unusual manifestations of aspergillosis.

Authors:  D W Denning
Journal:  Thorax       Date:  1995-07       Impact factor: 9.139

5.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

Review 6.  Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings.

Authors:  T Franquet; N L Müller; A Giménez; P Guembe; J de La Torre; S Bagué
Journal:  Radiographics       Date:  2001 Jul-Aug       Impact factor: 5.333

7.  Thoracic manifestations of aspergillosis.

Authors:  D L Klein; G Gamsu
Journal:  AJR Am J Roentgenol       Date:  1980-03       Impact factor: 3.959

8.  Airway obstruction and acute respiratory failure due to Aspergillus tracheobronchitis.

Authors:  Christina Routsi; Panagiotis Kaltsas; Evangelos Bessis; Demetra Rontogianni; Spyros Kollias; Charis Roussos
Journal:  Crit Care Med       Date:  2004-02       Impact factor: 7.598

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 10.  Pulmonary aspergillosis: a clinical update.

Authors:  O S Zmeili; A O Soubani
Journal:  QJM       Date:  2007-06
View more
  3 in total

Review 1.  Endobronchial aspergilloma-a comprehensive literature review with focus on diagnosis and treatment modalities.

Authors:  Sam Ngu; Naureen Narula; Mohammad Abureesh; Jia Jian Li; Michel Chalhoub
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-18       Impact factor: 3.267

2.  Endobronchial aspergilloma associated with idiopathic pulmonary fibrosis: a case report and review of the literature.

Authors:  Qiu-Hong Li; Yi-Liang Su; Li-Kun Hou; Yuan Zhang; Yang Hu; Li Shen; Fen Zhang; Ying Zhou; Huiping Li
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  Obstructive Pneumonia Associated with Endobronchial Aspergilloma: Successful Treatment with Interventional Bronchoscopy and Antifungals.

Authors:  Masamichi Komatsu; Masanori Yasuo; Yosuke Wada; Munetake Takata; Hisanori Azuhata; Yuichi Ikuyama; Jumpei Akahane; Kei Sonehara; Atsuhito Ushiki; Hiroshi Yamamoto; Masayuki Hanaoka
Journal:  Intern Med       Date:  2022-02-08       Impact factor: 1.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.